Format

Send to

Choose Destination
Rev Clin Esp. 2017 Nov;217(8):473-477. doi: 10.1016/j.rce.2017.02.007. Epub 2017 Mar 18.

Cardiovascular safety of noninsulin antidiabetic drugs: facts and promises.

[Article in English, Spanish]

Author information

1
Servicio de Cardiología, Hospital Universitario Príncipe de Asturias; Departamento de Medicina y Especialidades Médicas, Facultad de Medicina y Ciencias de la Salud, Universidad de Alcalá, Alcalá de Henares, Madrid, España. Electronic address: alberto.garcia-lledo@uah.es.
2
EAP Cogolludo, Guadalajara, SESCAM; Cátedra SEMERGEN-Universidad de Alcalá, Alcalá de Henares, Madrid, España.
3
Unidad de Farmacología Clínica, Hospital Universitario Príncipe de Asturias; Departamento de Ciencias Biomédicas, Facultad de Medicina y Ciencias de la Salud, Universidad de Alcalá, Alcalá de Henares, Madrid, España.

Abstract

Non insulin antidiabetic drugs are widely used in patients with type 2 diabetes. However, the drugs' effect in terms of reducing cardiovascular risk has been the subject of controversy. In 2008, based on the evidence of cardiovascular risk resulting from the use of a number of non insulin antidiabetic drugs, the US Food and Drug Administration published directives on the need to perform cardiovascular safety studies. These directives have helped obtain more evidence, such that at present there are 2 families of drugs that can reduce cardiovascular risk. These recent data have helped us add the reduction of cardiovascular morbidity and mortality to the objective of controlling blood glucose. Nevertheless, research continues with the development of new long-term studies.

KEYWORDS:

Antidiabéticos orales; Cardiovascular risk; Diabetes mellitus; Oral diabetes drugs; Riesgo cardiovascular

PMID:
28318520
DOI:
10.1016/j.rce.2017.02.007

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center